Steritas_MoonFace_1_RT_ED_Feb5

Let's face it,

Steritas_MoonFace_2_RT_ED_Feb5(1)

Let's face it,
now that steroid-toxicity can be measured...

Steritas_MoonFace_3_RT_ED_Feb5(1)

Let's face it,
now that steroid-toxicity can be measured...
prescribing patterns need to change

Steritas_MoonFace_4 RT_ED_Feb5(1)

Let's face it,
now that steroid-toxicity can be measured...
prescribing patterns need to change

50 million people1

1% of the world's adult population is taking long-term glucocorticoids.

Top 10 most prescribed2

Oral steroids are in the top 10 most prescribed medications in the United States.

40% more cost3

Steroid-toxicity is linked to 40% of cost of healthcare for patients on glucocorticoids.

Glucocorticoids are overused and toxic: The Great Taper is on

For over 75 years, the world has been hooked on steroids as the first-line treatment for a wide range of conditions caused by inflammation. More than 50 million people (1% of the world’s adult population) take steroids long-term, and it is now clear that the burdens of steroid-toxicity outweigh many of their beneficial effects over time.  

The medical community agrees: now is the time to taper steroids and seek steroid-sparing alternatives. At Steritas, our mission is to alter steroid prescribing patterns through a public health initiative we call The Great TaperTM. The suite of tools we have developed to measure steroid-toxicity is a game-changer in this global effort.

STOX Suite adopted globally to counter the hidden epidemic of steroid-toxicity

Steritas_Website_WorldMap_1267x539pxl_Feb14_2024_VF

The STOX Suite

The first validated Clinical Outcome Assessments to measure steroid-toxicity

Our growing suite of tools is designed for use in:

  • Clinical research for the development of new steroid-sparing drugs and treatment protocols.
  • Health and economics outcomes research (HEOR) for the discovery of steroid-toxicity and hidden costs found in large datasets.
  • Routine practice to monitor emerging steroid-toxicity in clinic patients.
  • Direct-to-patient applications that help patients collaborate in their treatment.

 

The STOX® Suite provides a systematic approach to assess steroid-toxicity, comprising:

  • The GTI: calculates change scores across nine health domains in adults
  • The GTI-MD: quantifies change across four metabolic domains in claims and EMR data
  • The pGTI: captures the change scores in ten health domains in children 

 

These instruments have now been used in more than 25 disease indications across more than 1100 sites in 80 countries.

Steritas_STOX_Suite_KO_Logo_589x174pxl

Clinical outcome assessments

First-in-class instruments to quantify
steroid-toxicity

STOX Suite
steritas-gti

Glucocorticoid Toxicity Index

Calculates change scores across nine health domains in adults

Steritas GTI
Steritas_GTI-MD_STOX_Suite_Logos_KO_RGB_1300x176pxl_96dpi-1

GTI Metabolic Domains

Quantifies change across four metabolic domains

Steritas GTI-MD
Steritas_pGTI_STOX_Suite_Logos_KO_RGB_1300x176pxl_96dpi

Pediatric Glucocorticoid Toxicity Index

Captures the change scores in ten health domains in children

Steritas pGTI
"Trial sponsors have a great opportunity and challenge to demonstrate what they mean by steroid-sparing and how that translates into healthcare benefits such as reduced hospitalizations, and improved quality of life."

Sudhakar Sridharan, MD

Vice President in Medical Science & Strategy Division at PPD/ThermoFisher

Learn More
"The GTI is the first and only quantitative measure of steroid-toxicity - It allows us to quantify the scale of adverse reactions, helps us taper steroids, and look after our patients more effectively."

Wen Zhang, MD PhD

Professor Rheumatology at Peking Union Medical College Hospital (PUMCH), Beijing, China

Learn More
"Steroids have a role in treating so many diseases - and yet, they do not cure any of them."

John H. Stone, MD MPH

Professor of Medicine at Harvard Medical School, and the Edward A. Fox Chair in Medicine at the Massachusetts General Hospital

Learn More
"The GTI is being used in many trials around the world and the development of the GTI-MD should enable the majority of rheumatologists to quantify glucocorticoid toxicity in day-to-day practice."

Frank Buttgereit, MD

Professor of Rheumatology and Deputy Head of the Department of Rheumatology and Clinical Immunology at the Charite University Medicine (CCM) in Berlin

Learn More
"Anywhere that steroids are being used in clinical studies, especially randomized controlled studies, there is a place for the GTI."

Paul Brunetta, MD

Head of Clinical & Translational Science, Sana Biotechnology

Adjunct Associate Professor, Pulmonary and Critical Care Division,

University of California, San Francisco

Learn More

Find the right efficacy and safety outcome measure for your clinical trial or practice

STOX Suite

References

  1. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatol Oxf Engl. 2011;50:1982–1990.
  2. https://clincalc.com/DrugStats/Drugs/Prednisone 
  3. Laurence Fardet, MD, PhD, Irene Petersen, PhD, and Irwin Nazareth, MD, PhD Monitoring of Patients on Long-Term Glucocorticoid Therapy- A Population-Based Cohort Study. Medicine. Volume 94, Number 15, April 2011.